Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2016-09-26 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a company announcement dated 26 September 2016 from Novozymes regarding transactions under its share buy-back program. It details the number of shares repurchased, transaction values, and trading venues, along with regulatory references to the EU Market Abuse Regulation. The content focuses exclusively on the company's repurchase of its own shares and related trading data. There is no indication of financial results, earnings, management changes, or other report types. The document is lengthy and detailed but is clearly a disclosure of share repurchase transactions. According to the filing definitions, such a document fits the category 'Transaction in Own Shares' (POS).
2016-09-26 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions under Novozymes' stock buyback program, including specific share purchase numbers, prices, and transaction values. It references a stock buyback program initiated in 2016 and provides detailed trading data and transaction logs. There is no indication of financial statements, earnings data, management discussion, or other report content. The document is focused on the company's repurchase of its own shares, which fits the category of a share repurchase or issuance activity. Therefore, the document is best classified as a Transaction in Own Shares (POS) filing.
2016-09-26 English
Transaction in Own Shares 2016
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a 'stock buyback program' announced previously. This action directly relates to the company acquiring its own shares. The filing category that covers the report of the company buying back or selling its own shares is 'Transaction in Own Shares' (POS). The document is very short and mentions reading the full announcement in PDF, but the core content is the transaction itself, making POS a more specific fit than RPA or RNS, although it functions as a notification of the transaction.
2016-09-19 English
Transaction in Own Shares 2016
Transaction in Own Shares Classification · 100% confidence The document text is very short (270 characters) and describes a specific transaction: Novozymes buying back shares (5,317,432 shares for 1,605.0 million DKK) under a previously announced share repurchase program. This directly relates to the company buying back its own stock. The final line, 'Læs hele meddelelsen i PDF format' (Read the full announcement in PDF format), suggests this is a brief announcement rather than the full detailed report. The most specific category for reporting the company buying back its own shares is 'Transaction in Own Shares' (POS).
2016-09-19 Danish
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Novozymes regarding transactions related to its share buy-back program, including specific data on the number of shares repurchased, prices, and transaction values. It references the EU Market Abuse Regulation and provides extensive trading data and contact information. There is no indication of financial statements, earnings data, management discussion, or other report content. The document is focused on the company's repurchase of its own shares, which fits the category of a Transaction in Own Shares (POS). The document length is substantial and contains detailed transaction data, confirming it is not a mere announcement of a report but a substantive disclosure of share repurchase activity.
2016-09-19 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement of transactions under Novozymes' stock buyback program, including the number of shares purchased, transaction values, and trading data. It references a specific stock buyback program initiated in 2016 and provides detailed trading data and accumulated shares bought back. There is no indication of financial statements, earnings data, management discussion, or regulatory certifications. The content is focused on the company's repurchase of its own shares, which fits the category of a report on transactions in own shares (share repurchase). Therefore, the document is best classified as a Transaction in Own Shares (POS) filing.
2016-09-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.